期刊文献+

Association Between IL-6 (Interleukin-6) and Iron Status in Rheumatoid Arthritis Patients

Association Between IL-6 (Interleukin-6) and Iron Status in Rheumatoid Arthritis Patients
下载PDF
导出
摘要 The study was performed to determine whether the srum concentrations of IL (interleukin)-6 are elevated in patients with RA (rheumatoid arthritis) and to investigate the relationship between IL-6 levels and iron status in RA patients. 95 serum samples were obtained, 70 of them from patients with RA who had visited the department of Rheumatology at Al-Sadder medical city in Najaf governorate (Iraq) and 25 age and sex-matched healthy controls. The authors assessed the clinical parameters of the disease, including ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), and RF (rheumatoid factor). Serum levels of iron and TIBC (total iron binding capacity) were measured spectrophotometrically, while TS% (transferrin saturation percentage) and transferrin concentration were calculated mathematically. Serum concentrations of IL-6 (interleukin-6) and ferritin were measured using an ELISA (enzyme-linked immunosorbent assay). The results of serum concentration of IL-6 (interleukin-6) and ferritin were significantly elevated (P 〈 0.0001) in patients with RA compared to those of healthy controls. On the other hand, serum concentrations of iron, TIBC (total iron binding capacity), TS% (transferrin saturation percentage) and transferrin concentration were significantly decreased in patients with RA compared with those of healthy controls. These findings suggest that anemia is the most frequent observations in patients with RA and mostly associative with increasing level of interleukin-6.
出处 《Journal of Life Sciences》 2014年第5期404-409,共6页 生命科学(英文版)
关键词 Rheumatoid arthritis INTERLEUKIN-6 Iron status ACD (anemia of chronic diseases) proinflammatory cytokines. 白细胞介素-6 铁营养状况 类风湿关节炎 IL-6 患者 酶联免疫吸附测定法 类风湿性关节炎 转铁蛋白
  • 相关文献

参考文献30

  • 1M.C. Hochberg, A.J. Silman, J.S. Smolen, M.E Weinblatt, M.H. Weisman, Rheumatology. In: A.J. MacGregor, A.J. Silman, editors, Classi-fication and Epidemiology, 4th ed. Mosby, Spain, 2008, pp. 755-762.
  • 2I.B. Mclnnes, G. Schett, Cytokines in the pathogenesis of rheuma-toid arthritis, Nat. Rev. Immuno. 17 (2007) 429-442.
  • 3F. Brennan, J. Beech, Update on cytokines in rheumatoid arthritis, Curr. Opin. Rheumato. 119 (2007) 296-301.
  • 4L.C. Huber, O. Distler, I. Tamer, R.E. Gay, S. Gay, T. Pap, Synovial fibroblasts: Key players in rheumatoid arthritis, Rheumatology 45 (2006) 669-675.
  • 5Z. Szekanecz, A.E. Koch, Macrophages and their products in rheu-matoid arthritis, Curr. Opin. Rheumato. 119 (2007) 289-295.
  • 6R. Madhok, A. Crilly, J. Watson, H.A. Capell, Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity, Ann. Rheum. Dis. 52 (1993) 232-234.
  • 7L.S. Knudsen, I.J. Christensen, T. Lottenburger, M.N. Svendsen, H.J. Nielsen, L Nielsen, et al., Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis, Biomarkers 13 (2008) 59-78.
  • 8J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos Remus, J. Rovensky, E. Alecock, et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OP-TION study): A double-blind, placebo-controlled, Randomised Trial, Lancet 371 (2008) 987-997.
  • 9M.C. Genovese, J.D. McKay, E.L. Nasonov, E.F. Mysler, N.A. da Silva, E. Alecock, et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, Arthritis Rheum 58 (2008) 2968-2980.
  • 10P. Emery, E. Keystone, H.P. Tony, A. Cantagrel, R. van Vollenhoven, A. Sanchez, et al., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-turnout necrosis factor biologicals: Results from a 24-week multicentrerandomised placebo-controlled trial, Ann. Rheum. Dis. 67 (2008) 1516-1523.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部